0001735276-24-000009.txt : 20240220 0001735276-24-000009.hdr.sgml : 20240220 20240220160859 ACCESSION NUMBER: 0001735276-24-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Poulton Jeffrey V. CENTRAL INDEX KEY: 0001782962 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 24653318 MAIL ADDRESS: STREET 1: 300 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-02-15 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001782962 Poulton Jeffrey V. 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 0 1 0 0 EVP, Chief Financial Officer 0 Common Stock 2024-02-15 4 A 0 3278 0.0 A 19151 D Common Stock 2024-02-16 4 S 0 369 147.5 D 18782 D Common Stock 2024-02-16 4 S 0 518 148.24 D 18264 D Common Stock 2024-02-16 4 S 0 120 149.03 D 18144 D Common Stock 57 I by Managed Account On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the reporting person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. By: Stephen Hall, Attorney-in-Fact For: Jeffrey V. Poulton 2024-02-20